Abstract:The substantial growth of R&D expenditures over the last two decades, together with the continuous substitution of knowledge (intangible) capital for physical (tangible) capital in corporate production functions, has elevated the importance of R&D in the performance of business enterprises. At the same time, however, the evaluation of corporate R&D activities by investors is seriously hampered by antiquated accounting rules and insufficient disclosure by corporations. Despite the fact that the expected benefits of R&D stretch over extended periods of time, corporate investments in R&D are immediately written off in financial reports, leaving no trace of R&D capital on balance sheets and causing material distortions of reported profitability. After a brief review of statistics documenting the growth and economic importance of corporate R&D in the U.S., the article presents a comparison of R&D disclosure regulations among industrialized nations that shows U.S. rules to be the least flexible in allowing management discretion in how they measure and report R&D. Next the author surveys the large and growing body of empirical research on R&D, which provides strong testimony to the substantial contribution of R&D to corporate productivity and shareholder value. Moreover, despite widespread allegations of stock market “short termism” throughout the 1980s and early '90s, the research indicates “unequivocally” that capital markets consider investments in R&D as a significant value‐increasing activity. But if investors clearly demonstrate a willingness to take the long view of R&D, there is also evidence of undervaluation of some R&D‐intensive companies—particularly those with low profitability—as well as other potential costs to corporations and investors stemming from inadequate public information about R&D. To help correct the reporting biases and distortions of R&D, the author offers some suggestions for investors and analysts that follow R&D‐intensive companies. In particular, he proposes (1) adjustment of reported data to reflect the capitalization and amortization of (instead of expensing) corporate R&D and (2) the use of various quantitative measures for gauging research capabilities and output, including citations of the firm's patents and measures indicating the share of current revenues coming from products developed within recent years.

How Do Firm Characteristics Influence the Relationship between R&D and Firm Value?

R&D expenses and firm valuation: a literature review

Financial Market Reaction To R&D Volatility In The Pharmaceutical Industry. A Multi-Country Study

The effects of R&D and competition on firm value: International evidence

R&D Volatility and Market Value: the Role of Executive Overconfidence

The Impact of R&D Expenditures on Corporate Performance: Evidence from Slovenian and World R&D Companies

The capitalization, amortization, and value-relevance of R&D

Research and Development Expenses: Implications for Profitability Measurement and Valuation

Do R&D expenditures matter more than those of marketing to company performance? The moderating role of industry characteristics and investment density

Exploring asymmetric dynamics of R&D spending and firm value nexus: Insights from panel autoregressive distributed lag analysis

Factors affecting firm's R&D investment decisions

How does leverage affect R&D intensity and how does R&D intensity impact on firm value in South Korea?

To What Extent Do Earnings Affect the R&D Decision of Chinese Manufacturing Firms?

R&D AND CAPITAL MARKETS

External Financing, R&D Intensity, and Firm Value in Biotechnology Companies

Bounded Rationality Effect on Firm’s Choices on R&D Investments: A Model for Decision-Making Effectiveness Analysis

The impact of country-level corporate governance on research and development

Are the RD Costs Significant for the Company’s Market Value in a Normal (Non-Crisis) Decade? – Evidence From the Athens Stock Exchange

A model for R&D performance measurement

The Relationship Between R&D and Company Performance